





SHAREABLE PDF

# Reply: Is high-dose glucocorticoid beneficial in COVID-19?

Maryam Edalatifard<sup>1</sup>, Maryam Akhtari <sup>2,3</sup>, Mohammadreza Salehi<sup>4</sup>, Elham Farhadi<sup>2,3</sup>, Ahmadreza Jamshidi<sup>2</sup>, Mahdi Mahmoudi <sup>2,3</sup> and Abdolrahman Rostamian<sup>5</sup>

**Affiliations:** <sup>1</sup>Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran. <sup>2</sup>Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Inflammation Research Center, Tehran University of Medical Sciences, Tehran, Iran. <sup>4</sup>Dept of Infectious and Tropical Medicines, Tehran University of Medical Sciences, Tehran, Iran. <sup>5</sup>Rheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

**Correspondence:** Abdolrahman Rostamian, Rheumatology Research Center, Imam Khomeini Hospital, P.O. BOX: 1418419967, Tehran, Iran. E-mail: arostamian@tums.ac.ir



@ERSpublications

**Our clinical trial supports the beneficial use of a high dose of methylprednisolone for the treatment of severe COVID-19 patients.** <https://bit.ly/3qvc4Kz>

**Cite this article as:** Edalatifard M, Akhtari M, Salehi M, *et al.* Reply: Is high-dose glucocorticoid beneficial in COVID-19?. *Eur Respir J* 2021; 57: 2100324 [<https://doi.org/10.1183/13993003.00324-2021>].

This single-page version can be shared freely online.

Reply to V. Muthu and co-workers: